{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:25:23Z","timestamp":1790047523952,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With the continuous in-depth study of the interaction mechanism between viruses and hosts, the virus has become a promising tool in cancer treatment. In fact, many oncolytic viruses with selectivity and effectiveness have been used in cancer therapy. Human enterovirus is one of the most convenient sources to generate oncolytic viruses, however, the high seroprevalence of some enteroviruses limits its application which urges to exploit more oncolytic enteroviruses. In this study, coxsackievirus B5\/Faulkner (CV-B5\/F) was screened for its potential oncolytic effect against non-small cell lung cancers (NSCLCs) through inducing apoptosis and autophagy. For refractory NSCLCs, DNA-dependent protein kinase (DNA-PK) or ataxia telangiectasia mutated protein (ATM) inhibitors can synergize with CV-B5\/F to promote refractory cell death. Here, we showed that viral infection triggered endoplasmic reticulum (ER) stress-related pro-apoptosis and autophagy signals, whereas repair for double-stranded DNA breaks (DSBs) contributed to cell survival which can be antagonized by inhibitor-induced cell death, manifesting exacerbated DSBs, apoptosis, and autophagy. Mechanistically, PERK pathway was activated by the combination of CV-B5\/F and inhibitor, and the irreversible ER stress-induced exacerbated cell death. Furthermore, the degradation of activated STING by ERphagy promoted viral replication. Meanwhile, no treatment-related deaths due to CV-B5\/F and\/or inhibitors occurred. Conclusively, our study identifies an oncolytic CV-B5\/F and the synergistic effects of inhibitors of DNA-PK or ATM, which is a potential therapy for NSCLCs.<\/jats:p>","DOI":"10.1038\/s41392-023-01603-4","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T20:01:58Z","timestamp":1695585718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors"],"prefix":"10.1038","volume":"8","author":[{"given":"Bopei","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-4355","authenticated-orcid":false,"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators.","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 563\u2013591 (2022).","journal-title":"Lancet"},{"key":"1603_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccell.2020.12.005","volume":"39","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. The landscape of cell and gene therapies for solid tumors. Cancer Cell 39, 7\u20138 (2021).","journal-title":"Cancer Cell"},{"key":"1603_CR3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1603_CR4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/1060028017702654","volume":"51","author":"PA Corrigan","year":"2017","unstructured":"Corrigan, P. A., Beaulieu, C., Patel, R. B. & Lowe, D. K. Talimogene Laherparepvec: an oncolytic virus therapy for melanoma. Ann. Pharmacother. 51, 675\u2013681 (2017).","journal-title":"Ann. Pharmacother."},{"key":"1603_CR5","doi-asserted-by":"crossref","first-page":"101530","DOI":"10.1016\/j.tranon.2022.101530","volume":"25","author":"Y Su","year":"2022","unstructured":"Su, Y., Su, C. & Qin, L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl. Oncol. 25, 101530 (2022).","journal-title":"Transl. Oncol."},{"key":"1603_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S186337","volume":"9","author":"N Jayawardena","year":"2020","unstructured":"Jayawardena, N., Poirier, J. T., Burga, L. N. & Bostina, M. Virus-receptor interactions and virus neutralization: insights for oncolytic virus development. Oncolytic Virother. 9, 1\u201315 (2020).","journal-title":"Oncolytic Virother."},{"key":"1603_CR7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2326-6066.CIR-18-0309","volume":"6","author":"RA Berkeley","year":"2018","unstructured":"Berkeley, R. A. et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol. Res. 6, 1161\u20131173 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1603_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","volume":"10","author":"DR Shafren","year":"2004","unstructured":"Shafren, D. R. et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10, 53\u201360 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1603_CR9","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","volume":"72","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto, S. et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 72, 2609\u20132621 (2012).","journal-title":"Cancer Res."},{"key":"1603_CR10","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cam4.3143","volume":"9","author":"L Cai","year":"2020","unstructured":"Cai, L. & Liu, Z. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med. 9, 5210\u20135220 (2020).","journal-title":"Cancer Med."},{"key":"1603_CR11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","volume":"25","author":"S Doni\u0146a","year":"2015","unstructured":"Doni\u0146a, S. et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 25, 421\u2013426 (2015).","journal-title":"Melanoma Res."},{"key":"1603_CR12","unstructured":"US National Library of Medicine. ClinicalTrials. gov [2022-09-15]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01227551(2022)."},{"key":"1603_CR13","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.3390\/cancers13225687","volume":"13","author":"G Stewart","year":"2021","unstructured":"Stewart, G., Chantry, A. & Lawson, M. The use of oncolytic viruses in the treatment of multiple myeloma. Cancers 13, 5687 (2021).","journal-title":"Cancers"},{"key":"1603_CR14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18594-3","volume":"11","author":"J Davila-Calderon","year":"2020","unstructured":"Davila-Calderon, J. et al. IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex. Nat. Commun. 11, 4775 (2020).","journal-title":"Nat. Commun."},{"key":"1603_CR15","volume":"7","author":"R Zhu","year":"2018","unstructured":"Zhu, R. et al. Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg. Microbes Infect. 7, 2 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"1603_CR16","doi-asserted-by":"crossref","first-page":"48443","DOI":"10.18632\/oncotarget.10305","volume":"7","author":"K Li","year":"2016","unstructured":"Li, K. et al. A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1. Oncotarget 7, 48443\u201348455 (2016).","journal-title":"Oncotarget"},{"key":"1603_CR17","doi-asserted-by":"crossref","first-page":"eaam7996","DOI":"10.1126\/scitranslmed.aam7996","volume":"9","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 9, eaam7996 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1603_CR18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1089\/hum.2017.055","volume":"29","author":"Y Tan","year":"2018","unstructured":"Tan, Y. et al. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Hum. Gene. Ther. 29, 950\u2013961 (2018).","journal-title":"Hum. Gene. Ther."},{"key":"1603_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.virusres.2016.04.016","volume":"220","author":"S Smithee","year":"2016","unstructured":"Smithee, S., Tracy, S. & Chapman, N. M. Reversion to wildtype of a mutated and nonfunctional coxsackievirus B3CRE(2C). Virus Res 220, 136\u2013149 (2016).","journal-title":"Virus Res"},{"key":"1603_CR20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2009.10.005","volume":"396","author":"R Gomes","year":"2010","unstructured":"Gomes, R., Guerra-S\u00e1, R. & Arruda, E. Coxsackievirus B5 induced apoptosis of HeLa cells: effects on p53 and SUMO. Virology 396, 256\u2013263 (2010).","journal-title":"Virology"},{"key":"1603_CR21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.omto.2019.07.003","volume":"14","author":"H Deng","year":"2019","unstructured":"Deng, H. et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol. Ther. Oncolytics. 14, 266\u2013278 (2019).","journal-title":"Mol. Ther. Oncolytics."},{"key":"1603_CR22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fonc.2020.00549","volume":"10","author":"Y Morillon","year":"2020","unstructured":"Morillon, Y. et al. The use of a humanized NSG-\u03b22m-\/- model for investigation of immune and anti-tumor effects mediated by the bifunctional immunotherapeutic Bintrafusp Alfa. Front. Oncol. 10, 549 (2020).","journal-title":"Front. Oncol."},{"key":"1603_CR23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1399-3089.2004.00183.x","volume":"11","author":"SE Myers","year":"2004","unstructured":"Myers, S. E. et al. Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor. Xenotransplantation 11, 536\u2013546 (2004).","journal-title":"Xenotransplantation"},{"key":"1603_CR24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1603_CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99\u2013103 (2017).","journal-title":"Nature"},{"key":"1603_CR26","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1128\/JVI.00321-06","volume":"80","author":"K Machida","year":"2006","unstructured":"Machida, K. et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol. 80, 7199\u20137207 (2006).","journal-title":"J. Virol."},{"key":"1603_CR27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/21505594.2016.1144001","volume":"7","author":"I Mart\u00ednez","year":"2016","unstructured":"Mart\u00ednez, I. et al. Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. Virulence 7, 427\u2013442 (2016).","journal-title":"Virulence"},{"key":"1603_CR28","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.18632\/oncotarget.15062","volume":"8","author":"T Sun","year":"2017","unstructured":"Sun, T., Li, X. & Shen, P. Modeling amplified p53 responses under DNA-PK inhibition in DNA damage response. Oncotarget 8, 17105\u201317114 (2017).","journal-title":"Oncotarget"},{"key":"1603_CR29","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/onc.2012.257","volume":"32","author":"MA Serrano","year":"2013","unstructured":"Serrano, M. A. et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 32, 2452\u20132462 (2013).","journal-title":"Oncogene"},{"key":"1603_CR30","doi-asserted-by":"crossref","first-page":"629008","DOI":"10.3389\/fonc.2021.629008","volume":"11","author":"H Zhao","year":"2021","unstructured":"Zhao, H., Zhang, X., Wang, M., Lin, Y. & Zhou, S. Stigmasterol simultaneously induces apoptosis and protective autophagy by inhibiting Akt\/mTOR pathway in gastric cancer cells. Front. Oncol. 11, 629008 (2021).","journal-title":"Front. Oncol."},{"key":"1603_CR31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594\u2013601 (2004).","journal-title":"Nat. Med."},{"key":"1603_CR32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.cdd.4401833","volume":"13","author":"B He","year":"2006","unstructured":"He, B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 13, 393\u2013403 (2006).","journal-title":"Cell Death Differ"},{"key":"1603_CR33","doi-asserted-by":"crossref","first-page":"jcs240622","DOI":"10.1242\/jcs.240622","volume":"134","author":"HB Ranjitha","year":"2020","unstructured":"Ranjitha, H. B. et al. Foot-and-mouth disease virus induces PERK-mediated autophagy to suppress the antiviral interferon response. J. Cell Sci. 134, jcs240622 (2020).","journal-title":"J. Cell Sci."},{"key":"1603_CR34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89\u2013102 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1603_CR35","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/emboj.2013.203","volume":"32","author":"H Cheon","year":"2013","unstructured":"Cheon, H. et al. IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32, 2751\u20132763 (2013).","journal-title":"EMBO J."},{"key":"1603_CR36","first-page":"E6310","volume":"115","author":"Q Ding","year":"2018","unstructured":"Ding, Q. et al. Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc. Natl Acad. Sci. USA 115, E6310\u2013E6318 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1603_CR37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/15548627.2021.1959086","volume":"18","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. STING1 is essential for an RNA-virus triggered autophagy. Autophagy 18, 816\u2013828 (2022).","journal-title":"Autophagy"},{"key":"1603_CR38","doi-asserted-by":"crossref","first-page":"110856","DOI":"10.1016\/j.celrep.2022.110856","volume":"39","author":"RS Singh","year":"2022","unstructured":"Singh, R. S. et al. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep. 39, 110856 (2022).","journal-title":"Cell Rep."},{"key":"1603_CR39","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1128\/JVI.00748-16","volume":"90","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. RIG-I-mediated STING upregulation restricts herpes simplex virus 1 infection. J. Virol. 90, 9406\u20139419 (2016).","journal-title":"J. Virol."},{"key":"1603_CR40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s13238-021-00869-0","volume":"13","author":"J Bai","year":"2022","unstructured":"Bai, J. & Liu, F. Nuclear cGAS: sequestration and beyond. Protein Cell 13, 90\u2013101 (2022).","journal-title":"Protein Cell"},{"key":"1603_CR41","doi-asserted-by":"crossref","first-page":"108490","DOI":"10.1016\/j.celrep.2020.108490","volume":"33","author":"S Cui","year":"2020","unstructured":"Cui, S. et al. Nuclear cGAS functions non-canonically to enhance antiviral immunity via recruiting methyltransferase Prmt5. Cell Rep. 33, 108490 (2020).","journal-title":"Cell Rep."},{"key":"1603_CR42","doi-asserted-by":"crossref","first-page":"e0010522","DOI":"10.1128\/jvi.00105-22","volume":"96","author":"P Yang","year":"2022","unstructured":"Yang, P. et al. Atomic structures of coxsackievirus B5 provide key information on viral evolution and survival. J. Virol. 96, e0010522 (2022).","journal-title":"J. Virol."},{"key":"1603_CR43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jmv.21100","volume":"80","author":"J Ahn","year":"2008","unstructured":"Ahn, J. et al. Primary neurons become less susceptible to coxsackievirus B5 following maturation: the correlation with the decreased level of CAR expression on cell surface. J. Med. Virol. 80, 434\u2013440 (2008).","journal-title":"J. Med. Virol."},{"key":"1603_CR44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10735-006-9055-4","volume":"37","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J. Mol. Histol. 37, 153\u2013160 (2006).","journal-title":"J. Mol. Histol."},{"key":"1603_CR45","doi-asserted-by":"crossref","first-page":"e2016","DOI":"10.1002\/rmv.2016","volume":"29","author":"M Rasti","year":"2019","unstructured":"Rasti, M., Khanbabaei, H. & Teimoori, A. An update on enterovirus 71 infection and interferon type I response. Rev. Med. Virol. 29, e2016 (2019).","journal-title":"Rev. Med. Virol."},{"key":"1603_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-013-1825-1","volume":"385","author":"Z Chen","year":"2014","unstructured":"Chen, Z. et al. LY294002 and rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K\/AKT\/mTOR signaling pathway. Mol. Cell Biochem. 385, 169\u2013177 (2014).","journal-title":"Mol. Cell Biochem."},{"key":"1603_CR47","doi-asserted-by":"crossref","first-page":"610042","DOI":"10.3389\/fimmu.2021.610042","volume":"12","author":"E Giehl","year":"2021","unstructured":"Giehl, E. et al. In vivo priming of peritoneal tumor-reactive lymphocytes with a potent oncolytic virus for adoptive cell therapy. Front. Immunol. 12, 610042 (2021).","journal-title":"Front. Immunol."},{"key":"1603_CR48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcdb.2014.03.025","volume":"27","author":"EK Colvin","year":"2014","unstructured":"Colvin, E. K. & Scarlett, C. J. A historical perspective of pancreatic cancer mouse models. Semin. Cell Dev. Biol. 27, 96\u2013105 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1603_CR49","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang, M. et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm. Sin. B 11, 2983\u20132994 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"1603_CR50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/v13050718","volume":"13","author":"A Geisler","year":"2021","unstructured":"Geisler, A., Hazini, A., Heimann, L., Kurreck, J. & Fechner, H. Coxsackievirus B3-its potential as an oncolytic virus. Viruses 13, 718 (2021).","journal-title":"Viruses"},{"key":"1603_CR51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-013-2785-6","volume":"143","author":"WM Ciszewski","year":"2014","unstructured":"Ciszewski, W. M., Tavecchio, M., Dastych, J. & Curtin, N. J. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res. Treat 143, 47\u201355 (2014).","journal-title":"Breast Cancer Res. Treat"},{"key":"1603_CR52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ijrobp.2012.01.092","volume":"84","author":"X Sun","year":"2012","unstructured":"Sun, X. et al. Identification and characterization of a small inhibitory peptide that can target DNA-PKcs autophosphorylation and increase tumor radiosensitivity. Int J. Radiat. Oncol. Biol. Phys. 84, 1212\u20131219 (2012).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"1603_CR53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2017.04.023","volume":"400","author":"YH Wu","year":"2017","unstructured":"Wu, Y. H. et al. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer. Cancer Lett 400, 79\u201388 (2017).","journal-title":"Cancer Lett"},{"key":"1603_CR54","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-017-0939-0","volume":"12","author":"C Klein","year":"2017","unstructured":"Klein, C. et al. Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiat. Oncol. 12, 208 (2017).","journal-title":"Radiat. Oncol."},{"key":"1603_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches, L. C. et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically. Mol. Cancer Ther. 19, 13\u201325 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1603_CR56","volume":"9","author":"X Xiao","year":"2018","unstructured":"Xiao, X. et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat. Commun. 9, 4342 (2018).","journal-title":"Nat. Commun."},{"key":"1603_CR57","volume":"7","author":"Q Mao","year":"2018","unstructured":"Mao, Q. et al. A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5. Emerg. Microbes Infect. 7, 185 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"1603_CR58","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00705-016-2842-7","volume":"161","author":"F Gao","year":"2016","unstructured":"Gao, F. et al. An epidemic of coxsackievirus B3 infection in infants and children in Jiangsu Province, China: a prospective cohort study. Arch. Virol. 161, 1945\u20131947 (2016).","journal-title":"Arch. Virol."},{"key":"1603_CR59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jviromet.2005.05.005","volume":"128","author":"S Biacchesi","year":"2005","unstructured":"Biacchesi, S. et al. Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression. J. Virol. Methods 128, 192\u2013197 (2005).","journal-title":"J. Virol. Methods"},{"key":"1603_CR60","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3390\/v14081740","volume":"14","author":"R Xiong","year":"2022","unstructured":"Xiong, R. et al. Long-term infection and pathogenesis in a novel mouse model of human respiratory syncytial virus. Viruses 14, 1740 (2022).","journal-title":"Viruses"},{"key":"1603_CR61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1126\/science.aag3048","volume":"359","author":"DS Leeman","year":"2018","unstructured":"Leeman, D. S. et al. Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. Science 359, 1277\u20131283 (2018).","journal-title":"Science"},{"key":"1603_CR62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1593\/neo.08120","volume":"10","author":"DJ Junk","year":"2008","unstructured":"Junk, D. J. et al. Different mutant\/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 10, 450\u2013461 (2008).","journal-title":"Neoplasia"},{"key":"1603_CR63","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.molcel.2019.03.033","volume":"74","author":"H Chino","year":"2019","unstructured":"Chino, H., Hatta, T., Natsume, T. & Mizushima, N. Intrinsically disordered protein TEX264 mediates ER-phagy. Mol. Cell 74, 909\u2013921 (2019).","journal-title":"Mol. Cell"},{"key":"1603_CR64","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.0903559","volume":"184","author":"J Zhu","year":"2010","unstructured":"Zhu, J. et al. High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors. J. Immunol. 184, 5768\u20135776 (2010).","journal-title":"J. Immunol."},{"key":"1603_CR65","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.celrep.2019.01.105","volume":"26","author":"M Gentili","year":"2019","unstructured":"Gentili, M. et al. The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus. Cell Rep. 26, 2377\u20132393 (2019).","journal-title":"Cell Rep."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:04:01Z","timestamp":1700305441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01603-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}